Zentalis Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $235.68M, a 12.61% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $48.63M, a 398.72% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2025 was $5.39M.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $235.68M, a 8.62% decline from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $257.92M, a 49.98% increase from fiscal 2021.
- Zentalis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $171.97M, a 10.73% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $5.39M 10-K · filed 2026-03-26 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $235.68M 10-K · filed 2026-03-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $235.68M 10-Q · filed 2024-08-09 | |
| 2022-12-31 | $48.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $257.92M 10-K · filed 2025-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | |
| 2022-06-30 | $209.30M 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $171.97M 10-K · filed 2024-02-27 |
| 2021-09-30 | $162.22M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $155.31M 10-K · filed 2023-03-01 |
| 2020-09-30 | $155.31M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $172.37M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |